CAS-ViewAlert

View Alert




Originator:		National Patient Safety Alert - DHSC
Issue date:		21-Oct-2024 13:41:38
This alert has been issued to:
		Care Trusts Mental Health Trusts Specialists Trusts Learning Disabilities Trusts Mental Health & Social Care Trusts Ambulance Trusts Mental Health & Learning Disabilities Trusts Acute Trusts Community Trusts
		Other contacts Independent Healthcare Providers (registered with CAS) Clinical Commissioning Groups NHS Regional Offices Social Care Providers (registered with CAS) Special Health Authorities Territorial CMOs in Northern Ireland, Scotland & Wales GP - Locum NHS 111 and Out of hours providers GP Practices Integrated Care Boards DHSC Supply Disruption - Medicines Community Pharmacy Primary Care Networks GP Practices 1
Action category:		Action
Title:		UPDATE: Discontinuation of Kay-Cee-L (potassium chloride 375mg/ml) (potassium chloride 5mmol/5ml) syrup
Broadcast content:		*This NatPSA supersedes NatPSA/2024/008/DHSC* Kay-Cee-L^® (potassium chloride 5mmol/5ml) syrup will be discontinued from late November 2024 due to manufacturing and commercial issues. Sando-K^® (potassium bicarbonate 400mg and potassium chloride 600mg) effervescent tablets remain available and can support a full increase in demand. One effervescent tablet contains 12mmol potassium. Unlicensed potassium chloride oral solutions manufactured within the UK are available via Specials manufacturers, lead times vary. Care is needed to ensure selection of the most appropriate oral potassium supplement and delivery of the correct dosage. This National Patient Safety Alert provides further background, clinical information and actions for providers.
Additional information:		NHS England regions: please cascade this alert to community pharmacy.
Alert reference:		NatPSA/2024/011/DHSC
Action underway deadline:		24-Oct-2024
Action complete deadline:		31-Oct-2024
Attachments:		NatPSA_2024_011_DHSC.pdf